fbpx

Japan issues new travel advisory for UK, Denmark, other nations

US pharmaceutical company Johnson & Johnson applies for approval of its coronavirus vaccine in Japan

AA Images

Japan on Tuesday announced fresh travel measures for several countries with mandatory three-day COVID-19 quarantine for those coming from the UK, Denmark, Kazakhstan, and Tunisia.

Katsunobu Kato, chief Cabinet secretary and top spokesman for the Japanese government told a news conference that new measures will apply from Friday to all new entries and returnees, Tokyo-based Kyodo News reported.

In Japan, more people died from suicide last month than from Covid in all of 2020. And women have been impacted most

Besides, he added, the quarantine period has been extended to ten days from the current six days for those coming from India, Sri Lanka, Nepal, Pakistan, Bangladesh, and the Maldives.

Meanwhile, the US asked its citizens not to travel to Japan “due to the coronavirus situation in the country.”

Online babysitting service links Rwandan mothers with Japanese children

It updated its travel advisory on Japan to the highest on its four-tier scale – Level 4: Do Not Travel.

“Travelers should avoid all travel to Japan,” the US Centers for Disease Control and Prevention said.

According to the office of the Japanese prime minister, the country has registered 718,864 coronavirus cases, including 12,312 deaths.

Meanwhile, the US pharmaceutical company Johnson & Johnson failed the Japanese Health Ministry for approval of its coronavirus vaccine through its Japan-based local unit – Janssen Pharmaceutical K.K.

The company said it expects to deliver the vaccine to Japan by early 2022 if the country’s health authorities approve the vaccine.

Japan is already using Pfizer, Moderna, and AstraZeneca vaccines in its vaccination campaign which began late February.

There is no agreement between the Japanese government and Johnson & Johnson yet.

Japan signed agreements with Moderna to receive 50 million doses of the COVID-19 vaccine by September, 120 million doses from AstraZeneca, and 194 million doses from Pfizer.

Napomena o autorskim pravima: Dozvoljeno preuzimanje sadržaja isključivo uz navođenje linka prema stranici našeg portala sa koje je sadržaj preuzet. Stavovi izraženi u ovom tekstu autorovi su i ne odražavaju nužno uredničku politiku The Balkantimes Press.

Copyright Notice: It is allowed to download the content only by providing a link to the page of our portal from which the content was downloaded. The views expressed in this text are those of the authors and do not necessarily reflect the editorial policies of The Balkantimes Press.

Contact Us